in 2020

37.6 million people
globally were living with HIV, including 1.7 million children

HIV

34.7 million people
have died from AIDS-related illnesses since the start of the epidemic

27.4 million people
were accessing antiretroviral therapy in 2020, an increase of

2 m since 2019

26% of adults
living with HIV still miss out on HIV treatment, of whom the vast majority lives in low- and middle-income countries

47% of children

2 UNAIDS 2020 fact sheet (last accessed on 14 June 2021)
MPP’s WORK IN HIV

Note that supplies of MPP-Licensed products may occur outside of the licence(s) covered territory but where no patents are infringed, and/or in countries in the absence of registration via procurement channels, registration waivers and/or exemptions.

**dolutegravir (DTG) adult 50 mg**

**tenofovir disoproxil fumarate/lamivudine/dolutegravir (TDF/3TC/DTG – also known as TLD) 300/300/50 mg**

**tenofovir alafenamide/emtricitabine/dolutegravir (TAF/FTC/DTG) 25/200/50 mg**

**atazanavir/ritonavir (ATV/r) 300/100 mg**

Data as of 31 December 2020, provided by MPP’s sublicensees.
In March 2020, AbbVie issued a worldwide commitment not to enforce patents on lopinavir and ritonavir product, thus enabling supplies from MPP’s sublicensees outside of the MPP licence territory.

**Lopinavir/ritonavir (LPV/r) 100/25 mg & 200/50 mg**

- Covered territory: 54 countries
- Filed: 16 countries
- Approved: 43 countries
- Supplied: 111 countries

Data as of 31 December 2020, provided by MPP’s sublicensees

In March 2020, AbbVie issued a worldwide commitment not to enforce patents on lopinavir and ritonavir product, thus enabling supplies from MPP’s sublicensees outside of the MPP licence territory.

**Lopinavir/ritonavir (LPV/r) paediatric 40/10 mg**

- Covered territory: 102 countries
- Filed: 2 countries*
- Approved: 11 countries
- Supplied: 46 countries

Data as of 31 December 2020, provided by MPP’s sublicensees

In March 2020, AbbVie issued a worldwide commitment not to enforce patents on lopinavir and ritonavir product, thus enabling supplies from MPP’s sublicensees outside of the MPP licence territory.

*For confidentiality purposes, countries will be disclosed when approval from a stringent regulatory authority (SRA) for this product has been granted to more than one sublicensee.
Dolutegravir either on its own or in combination (TLD) has been supplied in **113 countries**

> **27.3 million**

patient-years of treatments have been supplied between 2017-2020

**34% & 12%**
decline in average price of DTG and TLD respectively between 2017-2020

**CUMULATIVE PACKS (30’S) OF DTG AND TLD SOLD BY MPP LICENSEES**

<table>
<thead>
<tr>
<th>Year</th>
<th>DTG 50mg</th>
<th>TLD</th>
<th>Grand Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>1.5M</td>
<td>113M</td>
<td>12.0M</td>
</tr>
<tr>
<td>2018</td>
<td>2.1M</td>
<td>5.5M</td>
<td>196.1M</td>
</tr>
<tr>
<td>2019</td>
<td>83.0M</td>
<td>196.1M</td>
<td>333.5M</td>
</tr>
<tr>
<td>2020</td>
<td>12.0M</td>
<td>333.5M</td>
<td></td>
</tr>
</tbody>
</table>

**TOP 10 COUNTRIES SUPPLIED IN 2020 WITH DTG AND/OR TLD COMBINATIONS THROUGH OUR LICENSEES**

<table>
<thead>
<tr>
<th>Country</th>
<th>DTG 50mg</th>
<th>TLD</th>
<th>Estimated number of people living with HIV (Source UNAIDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botswana</td>
<td>21,120</td>
<td>5,530,492</td>
<td>380,000</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>1,015,544</td>
<td>4,906,285</td>
<td>670,000</td>
</tr>
<tr>
<td>Kenya</td>
<td>1,952,176</td>
<td>11,110,778</td>
<td>1,500,000</td>
</tr>
<tr>
<td>Malawi</td>
<td>605,693</td>
<td>13,593,432</td>
<td>1,100,000</td>
</tr>
<tr>
<td>Mozambique</td>
<td>451,208</td>
<td>11,099,983</td>
<td>2,200,000</td>
</tr>
<tr>
<td>Nigeria</td>
<td>877,683</td>
<td>9,041,824</td>
<td>1,800,000</td>
</tr>
<tr>
<td>South Africa</td>
<td>1,462,582</td>
<td>28,075,902</td>
<td>7,500,000</td>
</tr>
<tr>
<td>Tanzania</td>
<td>537,345</td>
<td>15,884,050</td>
<td>1,700,000</td>
</tr>
<tr>
<td>Uganda</td>
<td>457,665</td>
<td>12,024,169</td>
<td>1,500,000</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>0</td>
<td>7,481,418</td>
<td>1,400,000</td>
</tr>
</tbody>
</table>

**NEW COUNTRIES SUPPLIED IN 2020**

<table>
<thead>
<tr>
<th>Country</th>
<th>DTG 50mg</th>
<th>TLD</th>
<th>Estimated number of people living with HIV (Source UNAIDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angola</td>
<td>51,288</td>
<td>558,213</td>
<td>340,000</td>
</tr>
<tr>
<td>Chad</td>
<td>-</td>
<td>66,216</td>
<td>120,000</td>
</tr>
<tr>
<td>Ecuador</td>
<td>11,459</td>
<td>6,096</td>
<td>47,000</td>
</tr>
<tr>
<td>Eritrea</td>
<td>252</td>
<td>119,800</td>
<td>14,000</td>
</tr>
<tr>
<td>Gambia (the)</td>
<td>9,066</td>
<td>94,316</td>
<td>28,000</td>
</tr>
<tr>
<td>Indonesia</td>
<td>150,000</td>
<td>419,824</td>
<td>640,000</td>
</tr>
<tr>
<td>Niger</td>
<td>14,121</td>
<td>62,952</td>
<td>33,000</td>
</tr>
<tr>
<td>Panama</td>
<td>10,130</td>
<td>99,583</td>
<td>26,000</td>
</tr>
<tr>
<td>Philippines</td>
<td>5,250</td>
<td>197,260</td>
<td>97,000</td>
</tr>
<tr>
<td>Thailand</td>
<td>102,261</td>
<td>61,580</td>
<td>470,000</td>
</tr>
</tbody>
</table>
globally, an estimated 58 million people have chronic hepatitis C infection with an important proportion developing cirrhosis or liver cancer.

direct-acting antiviral medicines (DAAs) can cure >95% of patients.

But still, access to diagnosis and treatment is low, especially in low- and middle-income countries, where the vast majority of people with the virus live.

Access to hepatitis C treatment is improving but remains too limited.

In 2019, 21% of those living with the HCV infection knew their diagnosis.

Of those diagnosed with chronic HCV infection, 9.4 million people (62%) had been treated with DAAs by the end of 2019.

Much more needs to be done to achieve 80% HCV treatment target by 2030.

MPP’s WORK IN HEPATITIS C

Note that supplies of MPP-licensed products may occur outside of the licence(s) covered territory but where no patents are infringed, and/or in countries in the absence of registration via procurement channels, registration waivers and/or exemptions.

**1. daclatasvir (DAC) 30 mg and 60 mg**

- **Covered Territory:** 112 countries
- **Filed:** 18 countries
- **Approved:** 34 countries
- **Supplied:** 34 countries

Data as of 31 December 2020, provided by MPP’s sublicensees.

**2. daclatasvir + sofosbuvir (DAC + SOF) 60/400 mg**

- **Covered Territory:** 97 countries
- **Filed:** 9 countries
- **Approved:** 10 countries
- **Supplied:** 9 countries

Data as of 31 December 2020, provided by MPP’s sublicensees.
MPP's WORK IN HEPATITIS C

Daclatasvir has been commercialised in more than 1 million treatments* have been made available till Dec 2020.

~85% decline in average price per treatment (DAC 60mg) between 2016 to 2020.

VOLUMES VS PRICE OF GENERIC DACLATASVIR SALES

Data as of December 2020

NEW COUNTRIES SUPPLIED IN 2020

(Data as of December 2020)

1 HCV treatment = 12 weeks therapy (3 packs)
Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. A global total of 206,030 people with multidrug- or rifampicin-resistant TB (MDR/RR-TB) were officially diagnosed and notified in 2019, a 10% increase from 2018. Ending the TB epidemic by 2030 is among the health targets of the Sustainable Development Goals (SDGs). To meet this target, faster-acting and better therapies to treat TB are urgently needed, particularly for MDR-TB.

World Health Organization, Fact Sheet, Tuberculosis, October 2020 (website accessed on 14 June 2021)